1. No category

ews
Global Virus Network Adds University at Buffalo
(USA), CReSA (Spain) as Newest Centers of Excellence
GVN recently announced the induction of the University at Buffalo (UB), State
University of New York (SUNY) and the Centre De Recerca En Sanitat Animalas
(CReSA) at the Universitat Autònoma de Barcelona (UAB) in Barcelona, Spain
as its newest Centers of Excellence. There are now 34 GVN Centers of
Excellence in 24 countries.
GVN Center
of Excellence
Director Dr.
Gene Morse
Spring/Summer 2015
Volume 5, Issue 1
Global Virus Network
Elects Business Leader
N. Scott Fine as
Chairman of the Board
of Directors
UB’s distinguished HIV and hepatits C virus (HCV) Clinical
Pharmacology Laboratory is an
internationally recognized leader
in antiviral pharmacology and
therapeutics and has been conducting antiviral research since the
beginning of the HIV epidemic.
“The inclusion of UB’s HIV and HCV
Clinical Pharmacology Laboratory
in the GVN reflects our ongoing
transition from a national program
to a partner in the development of
antivirals for global infectious diseases that challenge
public health. This opportunity will also allow our ongoing capacity building programs in Zimbabwe and
neighboring African countries to expand to address
the needs of additional resource limited countries in
other geographic locations,” said Dr. Gene D. Morse,
Director of UB’s GVN Center of Excellence, SUNY
Distinguished Professor, Associate Director at the NYS
Center of Excellence in Bioinformatics and Life Sciences,
and Co-Director of the SUNY Global Health Institute.
CReSA is an international leader in research on animal
health and its implications for human health. With an
enhanced BSL-3 laboratory facility, CReSA’s multidisciplinary research
groups are focused on
basic science, epidemiology, and vaccine and
diagnostic development
for notifiable zoonotic
diseases such as West
Nile Virus, Rift Valley
Fever, Chikungunya,
Bluetongue,
continued on p.2
GVN Center of Excellence
Director Dr. Joaquim Segalés
CReSA Facilities at the
Universitat Autònoma de
Barcelona Campus
On January 8, GVN announced the
election of finance and business
leader N. Scott Fine as Chairman of
the Board of Directors. Mr. Fine succeeds the outgoing Board Chairman,
attorney Timothy C. Moynahan, who
will take on a new role as Board Vice
Chairman.
“Mr. Fine brings not only exceptional
business skills and acumen to GVN
but an undeniable passion for
improving the health of humanity,”
said GVN co-founder and Scientific
Director Dr. Robert C. Gallo. “We are
delighted to be able to call him colleague, partner, and Chairman.”
Mr. Fine has more than 35 years experience in investment banking and
corporate finance, working on a multitude of debt and equity financings,
mergers and acquisitions, strategic
advisory work, and corporate restructurings. He has worked in the healthcare, biotechnology, and medical
continued on p.2
VN
From the G
President
Dear GVN Friends and Colleagues,
Even as the Ebola crisis continues to take an
increasing toll in West Africa, we look for lessons learned and ways to improve detection,
response, and action when the next viral outbreak occurs. A few weeks ago, GVN penned
an editorial for the Baltimore Sun on this
topic. Dr. Robert Gallo, Dr. Diane Griffin, the
Chairperson of GVN’s Board N. Scott Fine,
Dr. Sharon Hrynkow,
President, GVN
and I made a case for training of scientists in
[email protected]
EVERY country as part of a global preparedness strategy. This was important since many plans now in development and implementation call for increased methods of rapid
response and reporting, and also for skilled experts to travel to outbreak regions to assist. Our piece served as a reminder that longterm planning must include development of local talent as part of a
comprehensive strategy. We closed with,
“Acting together, and with urgency, we can safeguard our future
against pandemics by supporting a cadre of well-trained medical
virologists globally. Without such a force of viral disease experts,
we are all at risk.” The full text of the article is available at: http://
www.baltimoresun.com/news/opinion/oped/bs-ed-gvn-20150420story.html
GVN is committed to training the next generation of medical virologists, through short-term programs and longer-term opportunities.
One of our flagship programs is the GVN short course in medical
virology, to take place once again in Baltimore and to be held July
5-11. This course brings emerging virologists at the post-doctoral
and assistant professor level together with world leaders in medical
virology, including Dr. Robert Gallo, Dr. Ab Osterhaus, Dr. Diane
Griffin and Dr. Peter Palese, for a week of didactic and practical
sessions, and for special sessions at the White House and NIH.
You can read more about the short course on page 6 of this issue.
At the time of this writing, we are making final plans for the GVN
annual meeting, this year to be hosted by the China GVN. Among
the topics to review with GVN Center Directors from around the
world will be how we as a community can work more effectively to
inspire young people into the field of medical virology and how we
can maintain a pipeline of medical virologists for the future, the
very safety net that we need in the face of novel viral threats.
Sincerely,
Sharon H. Hrynkow, PhD
2 GVN VIRIONews
New Centers of Excellence
from p.1
Schmallenberg, Avian Influenza, MERS-coronavirus,
and pestiviruses; as well as endemic animal
viruses that cause significant economic losses
to agriculture such as porcine reproductive and
respiratory syndrome, porcine circovirus type 2,
and swine influenza.
“We are thrilled to join the Global Virus Network
as a Center of Excellence,” said Dr. Joaquim Segalés,
Director of both CReSA and the new GVN Center
of Excellence. “GVN will expand CReSA’s international reach, offer new opportunities for collaboration with the top virus researchers around
the world, and will help us further our goal of
achieving ‘one world, one health.’”
N. Scott Fine
from p.1
device sectors, including with Research Medical,
a specialty medical device manufacturer, on a
strategic equity alliance with The Tempo Group
of Jakarta, Indonesia. He was the lead investment banker on the Initial Public Offerings for
Med-Design Corporation, a specialty medical
device company, and Keurig Green Mountain
Coffee Roasters, among other leadership roles.
Mr. Fine is currently Executive Chairman of CTD
Holdings, Inc., a biotechnology company with
an orphan drug designation for the treatment
of Niemann-Pick Type C; the sole Director of
Better Place, Inc.; and is a member of the Board
of Directors of Kenon Holdings Ltd, a spin-off
from the Israel Corporation Ltd., and Forward
Industries, where he serves as a Director as well
as Chairman of the Audit Committee.
Mr. Fine supports a range of philanthropic and
humanitarian efforts, serving as a Director for
Operation Respect, a global anti-bullying nonprofit; as a Trustee for the American Air
Museum in Britain; and is an active participant
in the Medal of Honor Foundation and the
Intrepid Museum Foundation.
“I am honored to have been elected by the
Board of GVN as its Chairman, and I look forward to working with Dr. Gallo, Dr. Hrynkow,
and the full Board, to continue to build the GVN
on the platform so well estalished through Tim
Moynahan’s leadership,” said Mr. Fine.
GVN Annual Meeting
in Beijing, China
北京 2015!
The Global Virus Network’s 7th Annual
Meeting is May 16th-19th, 2015 in
Beijing, China. This year’s meeting is
hosted by the Beijing University of
Technology of the China GVN under
the leadership of Dr. Yi Zeng. The meeting brings together the Directors and
leading researchers from GVN’s 34
Centers of Excellence around the
world plus local guests to discuss the
latest research on HIV, Ebola, Influenza,
Dengue, and other key viral threats.
The conference program is available at:
http://gvn.org/beijing-meeting-2015.
Featured
Speakers
Dear Friends and Colleagues,
Dr. Yi Zeng
Dr. Ab Osterhaus
Conference Organizing Committee
Dr. Yi Zeng, China CDC and Beijing
University of Technology; Dr. Robert
Gallo, Institute of Human Virology,
University of Maryland School of
Medicine; Dr. William Hall, University
College Dublin; Dr. Ulrike Protzer,
Technical University Munich; Dr. Anders
Vahlne, Karolinska Institute; Dr. Maria
Salvato, Institute of Human Virology,
University of Maryland School of
Medicine; Dr. Xiaoping Dong and
Dr. Yiming Shao, China CDC; Dr.
Natalia Mercer, GVN; and Dr. Sharon
Hrynkow, GVN
VN
From the iG
tor
c
e
r
D
c
fi
i
t
Scien
Dr. Diane Griffin
Dr. Ulrike Protzer
Healthcare Pioneer Dr. Azad Moopen
Elected to Board of Directors of
the Global Virus Network
Dr. MV Pillai and Amanda Gutkin Named Senior Advisors
On January 8, GVN announced the election of Indian physician, entrepreneur, and philanthropist Azad Moopen,
MBBS, MD, DTCD to its Board of Directors.
Dr. Moopen is the Chairman and Managing Director of Aster
DM Healthcare, a healthcare conglomerate in the Middle
East and India with more than 200 network units inclusive
of hospitals, medical centers, pharmacies, diagnostics and
specialty centers, healthcare consultancy service, academics
& research to a medical college and an advanced Medical
city. A Physician-turned entrepreneur and philanthropist
When my colleagues and I cofounded the GVN in 2011, our
motivation was the strong belief
that there was a worldwide need
to strengthen the global safety net
against viral disease. We wanted
to connect Centers of Excellence
(CoE) in human viruses to facilitate groundbreaking research colRobert C. Gallo, MD,
GVN Scientific Director
laborations and provide top-level
train the next generation of virologists—wherever they are! I knew there was a critical
need for an organization like the GVN, but didn’t know
how far this would go or how enthusiastically it would be
received. I have not met a virus expert who was not
overwhelmingly enthusiastic when learning about the
GVN. Medical virologists worldwide understand the
reality and the enormity of the mortal threat posed by
existing, emerging, and reemerging viruses, and consider
the GVN to be an absolute and long overdue necessity.
GVN has been growing consistently. As we discuss on
the first page of this issue of Virion, we recently welcomed
two new CoE’s: the University at Buffalo (UB), State
University of New York (SUNY), USA with Gene D.
Morse, Pharm.D., FCCP, BCPS as Center Director and
the Centre de Recerca en Sanitat Animal (CReSA),
Barcelona, Spain with Joaquim Segalés, DVM, PhD, Dipl.
ECVP, Dipl. EC as Center Director. Today we are 34
Centers of Excellence in 24 countries, comprising expertise
in all classes of human viruses and I am looking forward
to seeing the directors and researchers from many of these
at the 7th Annual GVN Meeting this month in Beijing.
The power of GVN lies in its global reach, the depth of
its science, and its commitment to solving viral challenges facing humans.
We invite you to support GVN and join our mission.
Sincerely,
Robert C. Gallo, M.D.
continued on p.5
GVN VIRIONews 3
Virus Causing Cancer: HTLV-1
GVN Scandinavian-Baltic 2015
Regional Meeting
On June 8-10, 2015, GVN and its partners will
convene the 2nd Regional Scandinavian-Baltic
Conference on emerging viral threats.
Organized in cooperation with the GVN Center
of Excellence at the Karolinska Institute, it will
take place at the Djurönäset Conference Center,
45 kilometers south of Stockholm, Sweden. We
expect 100 participants from Sweden, Estonia,
Latvia, Lithuania, Ukraine, Russia, and the U.S.
to attend the meeting, scheduled for June 8-10.
These conferences provide unique opportunities
for junior researchers to interact with some of
the most prolific virologists in the Global Virus
Network. It also offers virologists working on
different viruses, vectors, and vaccines the
chance to learn about the current research of
their colleagues and to develop new collaborations and scientific exchanges.
COMING AND GOINGS
Departure of GVN Program Director Robert
Karrs: In January 2015, Robert Karrs took a new
position at the University of Maryland School of
Pharmacy. Robert was GVN’s first staff member
and played a key role organizing the initial GVN
conferences as well as developing some of the
first programs such as the 2014 Short Course in
Medical Virology. We wish him the best of luck
in his new endeavor!
GVN Welcomes New Intern
Kharl Galarpe (left): In
February 2015, Kharl joined
GVN as an intern. Kharl is a
student at Baltimore City
continued on p.6
4 GVN VIRIONews
5-10 million people globally are infected with a virus, HTLV-1, that,
for some, will lead blood cell cancers or debilitating neurologic disorders. But many do not know they are infected because countries
do not routinely screen blood supplies and infected patients are not
counseled on transmission.
Human T-cell Lymphotropic Virus-1 (HTLV-1) is a retrovirus discovered in 1980 by Dr. Robert Gallo, GVN co-founder and Scientific
Director and Director of the Institute of Human Virology at the University of Maryland School of Medicine, that causes blood cell cancers (leukemias and
lymphomas) and rare neurological diseases such as
HTLV-1-Associated Myelopathy or Tropical Spastic
Paraparesis (HAM/TSP). The
virus is sexually transmitted, although it can also be
transmitted mother-to-child,
through breast-feeding, by
needle sharing, and by blood
transfusions or organ transplants. There are no effective treatments or vaccines.
In 2014, GVN formed a task
force of international
experts on HTLV-1. The mission of the HTLV-1 Task
Force is to help speed the
Electron Micrograph of HTLV-1. Source CDC
discovery of drugs that will
stop virus transmission and progression from infection to disease;
and to educate the public about this and related viruses, the diseases
they cause, and how to prevent their spread. The Task Force consists
of experts from 11 countries* and is led by Dr. Gallo, Dr. Luc Willems
(Research Director, National Fund for Scientific Research at University of Liège) and Dr. Hideki Hasegawa (Director, Department of
Pathology, National Institute of Infectious Diseases, Japan).
*Members of the Task Force on HTLV are: Drs. Bob Gallo (GVN cofounder, Scientific Director, and Task Force Co-Chair, USA); Luc
Willems (Task Force Co-Chair, Belgium); Hideki Hasegawa (Task
Force Co-chair, Japan); William Hall (GVN co-founder, Ireland);
William Blattner (USA), Eduardo Gotuzzo (Peru); Hua Cheng
(USA), Viviana Simon (USA), Edward Murphy (USA), Anna Barbara
Carneiro-Proietti (Brazil), Yutaka Tagaya (USA), Masao Matsuoka
(Japan), Antoine Gessain (France), Umberto Bertazzoni (Italy),
Toshiki Watanabe (Japan), Renaud Mahieux (France), Yoshihisa
Tamano (Japan), Olivier Hermine (France), Vincenzo Ciminale
(Italy), Charles Bangham (UK), Luigi Chieco-Bianchi (Italy),
Roberto Accolla (Italy), G.P. Taylor (UK), Beatrice Macchi (Italy),
Steve Jacobson (USA), Joseph Harford (USA), Ali Bazarbachi
(Lebanon), Cal Macpherson (Grenada) and Raj Shah (CTIS, USA).
GVN Marks World Health
Day 2015 by Highlighting
Viral Causes of
Food-Borne Illness
On World Health Day, April 7, 2015, GVN called
attention to the impact of the viral causes of
food-borne illness including noroviruses,
hepatitis A virus, hepatitis E virus, and rotavirus.
Everyone is susceptible to these viruses and
taken together, they infect millions of people
each year and are responsible for more than
half a million deaths worldwide.
GVN’s statement and a separate fact sheet further
highlighted noroviruses, the most common cause of food-borne illness around the world. More commonly known as food
poisoning, the stomach bug, or the stomach flu, noroviruses cause between 19 and 21 million infections annually in the
US alone, and are responsible for up to 200,000 child deaths each year around the world. Although nearly everyone
experiences a norovirus infection at some point in his or her life, there are no vaccines to prevent infection from these
highly contagious viruses and no drugs to treat infections when they occur.
Electron
micrograph
of norovirus
in stool
GVN researchers are at the forefront of efforts to better understand these viruses and
develop drugs and vaccines to combat them. For example, GVN Board of Directors member
Dr. Raymond Schinazi and his colleagues at Emory University identified and his colleagues
identified compounds that showed antiviral activity against noroviruses in early studies.
In another key advance, work on mice noroviruses by researchers in Dr. Christiane
Wobus’ lab at the GVN Center of Excellence at the University of Michigan contributed to
the development of a new way to grow human noroviruses in the laboratory by
researchers in Dr. Stephanie Karst’s lab at the University of Florida.
GVN norovirus experts include:
n Christiane Wobus, PhD. Associate Professor, Department of Microbiology and Immunology, GVN Center of Excellence
at University of Michigan Medical School
n John Treanor, MD. GVN Center of Excellence Director and Chief of the Department of Medicine, Infectious Diseases,
University of Rochester Medical Center
n Heinz Ellerbrok, PhD. Deputy Head, Center for Biological Safety, GVN Center of Excellence at Robert Koch Institute,
Berlin, Germany
Healthcare Pioneers
from p.3
“Collaboration among the public and private sectors is
essential as we work as a global community to stem the
spread of deadly diseases. I look forward to working with
the Board and the GVN Centers of Excellence to stop viral
diseases in their tracks,” he added.
Dr. Azad Moopen
Dr. MV Pillai
Amanda Gutkin
from the South Indian state of Kerala, he holds an MBBS
and a Post Graduate in General Medicine from Calicut
Government Medical College in Kerala, and a Diploma in
Chest Diseases from Delhi University, India.
“It is an honor and privilege to join the GVN Board of
Directors at this pivotal point in time,” said Dr. Moopen.
Also joining GVN as Senior Advisors are Amanda Gutkin
and Dr. MV Pillai, MD. Ms. Gutkin co-founded GRG Partners,
a consultancy specializing in intermediation and fundraising for corporate acquisitions and high-end real estate
development projects with a focus on the Middle East,
Africa, the UK and the US. Dr. Pillai Professor of Oncology
at Thomas Jefferson University, Philadelphia and
Chairman of Oncology at Aster MedCity, among his other
leadership roles.
GVN VIRIONews 5
2nd Annual Short Course
in Medical Virology of the GVN:
July 5-11th, 2015—Apply Now!
GVN Hosts
Expert Webinars
for Businesses
on Chikungunya
and Influenza
The GVN Business Leadership Council hosted webinars in January and February
on priority viral threats.
Business leaders and members of the public connected
with leading GVN researchers to get updates on vaccine
and drug development and
risks to commerce.
Highlights
GVN ChikV Task Force
Co-Chair Dr. Scott
Weaver discussing
the current outbreak
in the Americas
Dr. Peter Palese
discusses seasonal and
More than 70 people from
pandemic influenza
across the United States,
during the webinar
Caribbean, South America,
and Europe logged in for the chikungunya
webinar, featuring GVN Chikungunya Task Force
Co-Chairs Dr. Scott Weaver of the University of
Texas Medical Branch in Galveston and Dr. Marc
Lecuit of the Pasteur Institute in Paris, France.
Dr. Lecuit discussed the epidemiology and disease course of chikungunya, drawing on his
experience investigating the 2005 outbreak
on La Reunion Island. Dr. Weaver discussed
the current outbreak in the Americas, its likely
spread, and the ongoing efforts to develop
drugs and therapeutics to combat the disease.
The influenza webinar featured one of the world’s
top flu researchers, Dr. Peter Palese of the Mount
Sinai Icahn School of Medicine, who provided an
update on the 2014-2015 flu epidemic; explained
why the annual flu vaccine was less effective this
year than in previous flu seasons; described his
research to develop a universal flu vaccine that
would obviate the need for annual vaccines.
Recordings of all GVN webinars are available
for download or streaming at the GVN website, www.gvn.org.
GVN will offer its Short Course in Medical
Virology in Baltimore, MD, Sunday, July 5,
2015 to Saturday, July 11, 2015. The oneweek intensive course covers the basic,
translational, and clinical aspects of
viruses that pose the greatest threats to
human health. Lecturers will be leading
medical virologists drawn from across
GVN’s Centers of Excellence globally. The
didactic program will examine state-of-theart aspects of research on a wide array of
viruses, and will include hands-on laboratory and clinical components. The program will encourage in-depth discussions and interaction with medical virology leaders in addition to providing
opportunities to meet with policymakers and leaders in Washington DC.
Please contact Dr. Natalia Mercer at [email protected] for more
information.
GVN Welcomes Dr. Natalia Mercer as its first
Science and Technology Fellow
In February, GVN welcomed Dr. Natalia Mercer,
PhD, a biochemist by training, as our first
Science & Technology Policy Fellow. Natalia
is responsible for conference and training programs including the GVN Annual Meeting,
establishing the GVN network of trainees,
and the organization’s Congressional liaison
efforts. Natalia obtained her PhD in 2006 from the Universidad
Nacional de La Plata, Argentina. As a postdoctoral Fellow at the
US National Cancer Institute (National Institutes of Health) in
Frederick, Maryland and at the University of Maryland School of
Medicine in Baltimore, Maryland, Natalia worked as a basic science researcher in diverse fields involving immunology, cancer,
and host-pathogen interactions through the lens of glycobiology.
Natalia also completed an assignment at the NCI Center for Cancer
Training in 2013, where she learned methods for grant portfolio
analysis. Natalia has been the driving force behind the preparations
for GVN Annual Meeting in Beijing and we are thrilled to welcome
her to the GVN team!
GVN thanks its BLC Members:
Comings and Goings
from p4
USTGlobal
6 GVN VIRIONews
®
Community College majoring in biotechnology and is supporting
a range of programs including the preparations for the GVN Annual
Meeting in Beijing, the planning of the 2015 Short Course in Medical
Virology, and the streamlining of GVN’s membership database.
Noteworthy Recent Publications
from GVN Researchers
Awards and Recognition
GVN applauds the
outstanding
achievements of its
members:
The following is a representation of recent notable publications from
GVN researchers. For a more complete list of recent publications by GVN
researchers, please visit: www.gvn.org
n Dr. Florence
Haseltine, PhD, MD,
GVN IT Consultant,
NIH Scientist
Dr. Florence Haseltine (left) with NIH Director
Emerita, and forFrancis Collins (center) and the Society for
mer Director of the Dr.
Women’s Health Research President and CEO
NIH Center of Pop- Phyllis Greenberger
ulation Research,
was honored by the Society for Women’s Health Research
(SWHR) for her outstanding leadership in founding SWHR
with the announcement of a new fellowship in her name
at the organization’s 25th Anniversary Gala in Washington,
DC. The Florence Haseltine Science Fellowship will help
train the next generation of women and men focusing
on the importance of sex and gender differences in
health and disease. SWHR, is a non-profit based in
Washington D.C. that is widely recognized as the thoughtleader in promoting research on biological differences
in disease and is dedicated to transforming women’s
health through science, advocacy, and education.
n Dr. Peter Palese,
GVN Center Director
and Professor and
Chair of the Department of Microbiology at the Mount
Sinai Icahn School
of Medicine, was
the recipient of the
Dr. Peter Palese
2015 Beijerinck
Virology Prize from Royal Netherlands Academy of Arts
and Sciences. The Beijerinck Virology Prize, which is
awarded every two years, was established in 1965 by
the M.W. Beijerinck Virology Fund, founded by Mr. and
Mrs. L.E. den Dooren de Jong in
memory of the virologist Martinus
Willem Beijerinck.
n Timothy Moynahan, Esq., Vice
Chair of the GVN Board of Directors, was an inaugural inductee
into the Post University Hall of
Fame, which honors the “best of
the best” of Post’s alumni, faculty
and staff, and supporters.
n Dunand, Carole J Henry, Paul E Leon, Kaval Kaur, Gene S Tan, Nai-Ying
Zheng, Sarah Andrews, Min Huang, et al. “Preexisting Human Antibodies
Neutralize Recently Emerged H7N9 Influenza Strains.” The Journal of
Clinical Investigation 125, no. 3 (2015): 1255–68. doi:10.1172/JCI74374.
n Fouts, Timothy R, Kenneth Bagley, Ilia J Prado, Kathryn L Bobb, Jennifer
A Schwartz, Rong Xu, Robert J Zagursky, et al. “Balance of Cellular and
Humoral Immunity Determines the Level of Protection by HIV Vaccines
in Rhesus Macaque Models of HIV Infection.” Proceedings of the National
Academy of Sciences of the United States of America 112, no. 9 (March 3,
2015): E992–99.
n He, Wenqian, Caitlin E Mullarkey, J Andrew Duty, Thomas M Moran,
Peter Palese, and Matthew S Miller. “Broadly Neutralizing Anti-Influenza
Virus Antibodies: Enhancement of Neutralizing Potency in Polyclonal
Mixtures and IgA Backbones.” Journal of Virology 89, no. 7 (2015): 3610–
18. doi:10.1128/JVI.03099-14.
n Kawabata, Shigeru, Alonso Heredia, Joell Gills, Robert R Redfield,
Phillip A Dennis, and Joseph Bryant. “Impact of HIV on Lung Tumorigenesis in an Animal Model.” AIDS (London, England) 29, no. 5 (March
13, 2015): 633–35.
n Krammer, Florian, and Peter Palese. “Advances in the Development
of Influenza Virus Vaccines.” Nature Reviews. Drug Discovery 14, no. 3
(2015): 167–82. doi:10.1038/nrd4529.
n Malvestutto, Carlos D, Qing Ma, Gene D Morse, James A Underberg,
and Judith A Aberg. “Lack of Pharmacokinetic Interactions between
Pitavastatin and Efavirenz or Darunavir/ritonavir.” Journal of Acquired
Immune Deficiency Syndromes (1999) 67, no. 4 (2014): 390–96.
doi:10.1097/QAI.0000000000000333.
n Martinez-Martin, Nadia, Abel Viejo-Borbolla, Rocío Martín, Soledad
Blanco, Jeffrey L Benovic, Marcus Thelen, and Antonio Alcamí. “Herpes
Simplex Virus Enhances Chemokine Function through Modulation of
Receptor Trafficking and Oligomerization.” Nature Communications 6
(2015): 6163. doi:10.1038/ncomms7163.
n Venuto, Charles S, Katie Mollan, Qing Ma, Eric S Daar, Paul E Sax,
Margaret Fischl, Ann C Collier, Kimberly Y Smith, Camlin Tierney, and
Gene D Morse. “Sex Differences in Atazanavir Pharmacokinetics and
Associations with Time to Clinical Events: AIDS Clinical Trials Group
Study A5202.” The Journal of Antimicrobial Chemotherapy 69, no. 12
(2014): 3300–3310. doi:10.1093/jac/dku303.
n Yan, Jiabin, Juan Carlos Zapata, Charles David Pauza, and Maria S
Salvato. “Modulation of SIV and HIV DNA Vaccine Immunity by Fas-FasL
Signaling.” Viruses 7, no. 3 (March 23, 2015): 1429–53.
n Zeremski, Marija, Rositsa B Dimova, Samantha Benjamin, Marina S
Penney, Martyn C Botfield, and Andrew H Talal. “Intrahepatic and
Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients
Treated With Telaprevir, Pegylated Interferon, and Ribavirin.” The Journal of Infectious Diseases, 2014. doi:10.1093/infdis/jiu807.
GVN Board of Directors Vice
Chair Timothy Moynahan
GVN VIRIONews 7
GVN Board of Directors
N. Scott Fine, Chairman. Executive Chairman of the
Board, CTD Holdings
Gina Adams. Corporate Vice President, Government
Affairs, Fedex
Andrew Cheng, M.D., PhD. Senior VP of Development
Operations, Gilead Sciences, Inc.
Matthew L. Evins, Treasurer. Chairman, Evins Ltd.
Mary Jane Gallo, USA
Robert C. Gallo, MD, GVN Co-Founder and Scientific
Director. Director, Institute of Human Virology at the
University of Maryland School of Medicine
Sharon H. Hrynkow, PhD, ex officio. President, GVN
Glenda Gray, MBBCh, FCPAED, President, Medical
Research Council of South Africa
William Hall, MD, PhD, GVN Co-Founder and Director,
Centre for Research in Infectious Diseases, University
College Dublin
William Kirwan, PhD, Chancellor, University System
of Maryland
Charles Modica, JD, Chairman of the Board of Trustees
and Chancellor, St. George’s University
Azad Moopen, MBBS, MD, DTCD, Chairman &
Managing Director, Aster DM Healthcare
Timothy Moynahan, Esq., Vice Chair. The Moynahan
Law Firm
Franco Nuschese, President, Georgetown
Entertainment Group
Sajan Pillai, CEO, UST Global
VIRION
Virion Guest Editor: Collin Weinberger, MPH
GVN Team
Sharon H. Hrynkow, PhD, President, [email protected]
Marcus Gallo, MS, Research Associate, [email protected]
Research, Analysis
Kharl Galarpe, Intern, [email protected]
Nora Grannell, Director of Public Relations, [email protected]
Florence Haseltine, PhD, MD, IT Consultant, [email protected]
Edward McSweegan, PhD, Program Director, [email protected]
HTLV and Chikungunya Task Forces, Post-Doc Program
Natalia Mercer, PhD, Science and Technology Fellow, [email protected]
Maria Salvato, PhD, Exec. Sec., Scientific Leadership Board,
[email protected]
Collin Weinberger, MPH, Project Director, [email protected]
Business Leadership Council
Send news items for future Virion issues to Nora Grannell, Director
of Public Relations [email protected]
8 GVN VIRIONews
Raymond Schinazi, PhD, Hon DSc, Professor of
Pediatrics and Director, Laboratory of Biochemical
Pharmacology, Emory University
Jeffrey Schragg, Secretary. Tax Partner at BDO
GVN Senior Advisors
Prudence Bushnell, Ambassador (Ret.); CEO of Sage
Associates; Founder of the Levitt Leadership Institute
at Hamilton College
Vint Cerf, PhD, Vice President and Chief Internet
Evangelist, Google
Nicolas De Santis, Secretary General, Gold Mercury
International
Jose Esparza, MD, PhD, Independent Advisor on
Vaccines, HIV/AIDS, and Global Health
Amanda Gutkin, UAE
William Haseltine, PhD, President, ACCESS Health
International, Inc.
Neal Lane, PhD, Former Science Advisor to the U.S.
President; Senior Fellow, Baker Institute; Professor, Rice
University
Romain Murenzi, PhD, Executive Director, The
Academy of Sciences for the Developing World
MV Pillai, MD, Professor of Oncology, Thomas Jefferson
University; Chair of Oncology, Aster MedCity
Stanley Plotkin, PhD, Emeritus Professor, University of
Pennsylvania
Raj Shah, Chairman & CEO, CTIS, Inc.
Please
Support
JOIN THIS YOUNG AND GROWING ORGANIZATION,
and consider making a tax-deductible contribution.
Your support today will help build our organization
and our critical programs to safeguard the health of
the global community against viral disease threats.
Please point your browser to www.gvn.org and click
the Donate button at the top of the page or send
your gift to:
Global Virus Network
801 W. Baltimore Street, Suite 519
Baltimore, MD 21201
All gifts will be acknowledged
in our annual report and in our Newsletter.
Thank you for your support!